Patients with Cerebral Venous Sinus Thrombosis in COVID-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia

Reports of COVID-19 vaccination adverse events, specifically thrombosis with thrombocytopenia syndrome (TTS) associated with either the Oxford-AstraZeneca vaccine (ChAdOx1 nCov-19) and Janssen/Johnson & Johnson (Ad26.COV2S), raised notice among physician specialists around the world. A group of experts affiliated with the Cerebral Venous Sinus Thrombosis With Thrombocytopenia Syndrome Study Group organized a study manifesting in an international registry of patients with cerebral venous sinus thrombosis (CVST) after they received a SARS-CoV-2 vaccination. They sought to understand better the clinical characteristics and outcomes of patients with CVST with TTS (CVST-TTS). Specifically, they sought to test whether patients with CVST-TTS would present clinical features and a degraded prognosis; in parallel, they studied patients with postvaccination CVST without TTS suggesting a clinical profile in this cohort similar to patients with CVST pre-COVID-19 pandemic.

In this study, the investigators describe the clinical characteristics and outcomes of patients diagnosed with CVST post-COVID-19 vaccination with and without TTS. TrialSite provides a brief summary breakdown for the c...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee